Bristol-Myers Squibb Company and Rigel Pharmaceuticals Inc. entered into a collaboration for the discovery, development and commercialization of cancer immunotherapies based on Rigel’s portfolio of small molecule TGF beta receptor kinase inhibitors.
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
